Syndax Pharmaceuticals, Inc. SNDX R2KR3KPHARMA
Company Overview
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Why Investors Should Care
Revenue has grown at a 75.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $172.35M (+627.8% YoY); net profit $-285.42M.
- Trailing 12 Months Year-on-year growth — revenue +91.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 75.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 75.35% |
| 1 Year: | 91.80% |
Stock Price Performance
| 1 Year: | +52.86% |
| 6 Months: | -6.84% |
| 3 Months: | +18.57% |
| 1 Month: | +4.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)53.47 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 75.3% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SNDX Syndax Pharmaceuticals, Inc. R2KR3KPHARMA | 20.56 | -8.19 | $1.82B | 0.00% | -66.67% | - | 75.35% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 305.00K | 305.00K | 305.00K | 1.19M | 379.00K | 379.00K | 379.00K | 380.00K | 379.00K | 379.00K | 379.00K | 380.00K | 379.00K | 379.00K | 379.00K | 380.00K | 379.00K | 379.00K | 12.38M | - | - | - | - | 0 | 0 | 0 | 3.50M | 12.50M | 20.04M | 37.96M | 45.87M | 64.86M | 72.79M |
| Operating Income | -5.54M | -5.86M | -4.68M | -8.75M | -8.63M | -15.24M | -11.14M | -13.18M | -13.84M | -15.45M | -19.49M | -19.75M | -18.95M | -17.84M | -19.33M | -14.81M | -15.37M | -13.15M | -14.21M | -15.10M | -16.61M | -19.85M | -19.86M | -27.16M | -22.33M | -20.03M | -36.86M | -37.72M | -35.14M | -46.02M | -49.68M | -56.35M | -79.51M | -74.22M | -89.58M | -83.76M | -69.35M | -57.43M | -34.20M | -39.99M |
| Net Income | -6.21M | -7.73M | -5.26M | -10.33M | -8.36M | -14.97M | -10.81M | -12.97M | -13.64M | -15.09M | -19.10M | -19.40M | -18.39M | -17.34M | -18.84M | -14.30M | -14.92M | -12.83M | -14.00M | -15.24M | -17.06M | -20.44M | -20.42M | -27.72M | -22.91M | -20.64M | -37.17M | -37.57M | -35.40M | -41.13M | -44.62M | -51.15M | -72.40M | -68.06M | -84.13M | -84.85M | -71.85M | -60.72M | -42.67M | -49.36M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.44 | -0.40 | -0.63 | -0.62 | -0.58 | -0.59 | -0.64 | -0.73 | -0.85 | -0.80 | -0.98 | -0.98 | -0.83 | -0.70 | -0.48 | -0.55 |
| R&D Expense | 2.27M | 2.97M | 2.59M | 4.79M | 6.13M | 12.27M | 8.47M | 9.55M | 9.86M | 12.19M | 16.60M | 15.34M | 14.85M | 14.10M | 15.82M | 11.28M | 12.29M | 9.92M | 9.50M | 9.56M | 10.94M | 14.41M | 15.52M | 21.87M | 16.87M | 25.61M | 30.02M | 29.73M | 26.90M | 34.05M | 34.76M | 39.09M | 56.49M | 48.66M | 70.97M | 61.64M | 62.23M | 56.28M | 58.84M | 68.04M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 627.00K | 1.22M | 2.11M | 1.52M | 1.52M | 1.52M | 139.71M | 0 | 0 | 23.68M | 172.35M |
| Operating Income | -21.33M | -20.51M | -43.77M | -61.95M | -75.88M | -57.54M | -71.42M | 26.22M | -151.76M | -229.95M | -339.67M | -273.08M |
| Net Income | -19.83M | -24.12M | -44.47M | -60.80M | -73.96M | -56.05M | -73.16M | 24.93M | -149.34M | -209.36M | -318.76M | -285.42M |
| Diluted EPS | - | - | - | - | - | -1.84 | -1.87 | 0.46 | -2.46 | -2.98 | -3.72 | -3.29 |
| R&D Expense | 10.18M | 9.55M | 31.66M | 48.20M | 60.11M | 42.99M | 50.44M | 88.25M | 118.50M | 163.03M | 241.65M | 258.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 89.90M | 109.01M | 137.19M | 83.94M | 63.52M | 300.61M | 449.66M | 497.24M | 612.88M | 724.82M | 529.71M |
| Total Equity | -128.47M | -152.57M | -252.41M | 84.14M | 104.32M | 53.05M | 31.60M | 252.19M | 408.37M | 467.45M | 554.20M | 288.12M | 64.63M |
| Cash & Equivalents | 10.10M | 10.01M | 23.18M | 23.84M | 35.17M | 33.77M | 24.61M | 115.24M | 221.97M | 74.36M | 295.39M | 154.08M | 134.93M |
| Total Liabilities | - | - | 23.20M | 24.87M | 32.87M | 30.89M | 31.93M | 48.42M | 41.29M | 29.79M | 58.68M | 436.69M | 465.08M |
| Current Liabilities | - | - | 4.85M | 10.37M | 15.80M | 16.11M | 18.37M | 18.87M | 20.68M | 29.07M | 58.10M | 103.55M | 120.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -35.16M | -47.37M | -68.53M | -50.61M | -71.26M | 29.13M | -133.68M | -160.60M | -274.90M | -322.98M |
| Investing Cash Flow | - | - | -18.28M | -17.07M | 51.40M | 12.78M | -142.53M | -40.87M | -186.19M | 117.61M | -219.78M | 290.04M |
| Financing Cash Flow | - | - | 54.20M | 75.72M | 15.73M | 28.57M | 304.42M | 118.46M | 172.25M | 264.13M | 353.37M | 13.68M |
| Capital Expenditure | -4.00K | -49.00K | -261.00K | -84.00K | -187.00K | - | -0 | -129.00K | -0 | -0 | -0 | -187.00K |
| Free Cash Flow | - | - | -35.42M | -47.45M | -68.72M | - | -71.26M | 29.00M | -133.68M | -160.60M | -274.90M | -323.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -3,271.6% | -3,587.4% | -2,939.0% | -5,001.7% | -3,792.9% | -4,708.2% | 18.8% | - | - | -1,434.4% | -158.4% |
| Net Margin % | - | -3,846.7% | -3,645.2% | -2,884.3% | -4,875.5% | -3,694.6% | -4,822.5% | 17.8% | - | - | -1,346.1% | -165.6% |
| ROE % | 13.0% | 9.6% | -52.9% | -58.3% | -139.4% | -177.4% | -29.0% | 6.1% | -31.9% | -37.8% | -110.6% | -441.6% |
| ROCE % | - | -24.1% | -44.4% | -51.0% | -111.9% | -127.4% | -25.4% | 6.1% | -32.4% | -41.4% | -54.7% | -66.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.18% | 9.02M | $176.25M |
| 2 | Kynam Capital Management, LP | 9.09% | 8.05M | $157.32M |
| 3 | Goldman Sachs Group Inc | 6.61% | 5.86M | $114.53M |
| 4 | State Street Corporation | 6.39% | 5.66M | $110.57M |
| 5 | Bank of America Corporation | 4.57% | 4.05M | $79.04M |
| 6 | Vanguard Capital Management LLC | 4.43% | 3.93M | $76.75M |
| 7 | Deerfield Management Company, L.P | 4.27% | 3.78M | $73.86M |
| 8 | Eversept Partners, LP | 3.16% | 2.80M | $54.68M |
| 9 | Geode Capital Management, LLC | 2.92% | 2.58M | $50.49M |
| 10 | Hood River Capital Management LLC | 2.89% | 2.56M | $50.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNDX
Two talks by Syndax executives will be webcast live from New York in September. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSkRjYnJBREhNeTM2Nzh5UnNMNjExam5IOEVEV1FpM29odldyOTE2d0NId3BSRDIxQ2FlbGdlVm9NckdhT0ZsSmVfZnFNTVFULUVQejdkY0RQV0xXeUpnRjdMcENncTE4Rnc0SDhXUWlLc29KcFNlWFRjVG9BMGFRSF96Z3U4VnhMUk05TE…
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOY3BRMWVyQy1scjlhWU9fLWFoTlk5YUhTUXFTbUNHeWtlNndPWFpWRDFPcUZQMmhSX1ZFalBmZU1yNmJ5dDUwZ1VHbmlQVGNBQ1ZPVk1kN2MtZDBkZjlBNnV6c3RIM3I2TUo5dEM4dkN4YkV0NkQtRTQ4REVIcmVMWTVyalVhNEd0OUZHVT…
Legal & General Group Plc Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOSHJHOEJjbHg2MU8wd3IzazNOR1BQbFpyTEE2SlpkWndEcS0wWWw5OHJzcncxV01EalFhZmw4YlFkc1NLOExPTE9KcE9SNFJvT2xzNEtTVXNqd3l0a2RvOVI0clRjQ29IRjMwM1V3RzJLNjE3WFJMaUdBMVhudWktNy0tMUd5YlZMX1pqX1…
(SNDX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOcXpPUnV3eHpQOS12WC1ReFBCRWdFU2JCVzhWcDJtdkpMb2VWM3EwclZzZ2drenlEdXdlX0VUd1piVmEydDNwNXJaY3dQTk1hTHJ1TWhpRVNMUUpoclFhcklsTzNIVWNfUG8yREdCT1ZncXdNX1BvbkxFS0xILU53TU4wWXBRUjUyWGpJSk…
Nineteen new employees get options to buy up to 175,000 Syndax shares. The options vest over four years. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQVWJzV0NTOVBBOURpQWdDTl9ubUNuUW5mRG9YRVhwVzJJMnNGbmJjRjFWRE9mT3k0ZUxrRk5kVm01Y3pJZ19Lc2E0SE1LSFFUUklKbGp3SnpJSzdEQnk5N3l3ckNPR2lXZ0NYUDE0dlhMbHdXZjd3d01iNExkY2lRYWsxWGNZTk9VVk5La1…
Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxPajFIUXlDNXBXTWl5MG1Rc0ttNzBKejIwN3o4V0tfMm9sRFRhMzZyNDF5UjktdGM3WFB2U2NGR0JwUl9hZE9ORTJxZ203UHNOOFQtV1F5d1YzTS1TUFF0T0N2a1lkRjhKQ2w2M1d5a3c3VkR0N2psRHlabkpydHMxNWV6SzNRYjIwN3A4MH…
SNDX — Frequently Asked Questions
What is the current share price of Syndax Pharmaceuticals, Inc. (SNDX)?
As of 2026-09-07 16:24 PDT, Syndax Pharmaceuticals, Inc. (SNDX) trades at $20.56 on NasdaqGS. Its 52-week range is $13.11 to $25.15.
What is the market capitalisation of SNDX?
Syndax Pharmaceuticals, Inc. (SNDX) has a market capitalisation of $1.82B on NasdaqGS.
What is the P/E ratio of SNDX?
SNDX trades at a trailing price-to-earnings (P/E) ratio of -8.19. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 120.71.
Is SNDX a good stock to buy?
This page provides a data-driven analysis of Syndax Pharmaceuticals, Inc. (SNDX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.